Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Second-line chemo sets benchmark in biliary tract cancers

Publish date:: June 6, 2019

Key clinical point: Modified FOLFOX extended survival in previously treated advanced biliary tract cancers, though modest benefit and moderate toxicity suggest an unmet need for new treatment approaches.

Major finding: Risk of death was cut by 31% with addition of chemotherapy, though grade 3-4 adverse events were more common, and there were some chemotherapy-related deaths reported.

Study details: Results of ABC-06, a prospective randomized phase 3 study randomizing a total of 162 patients previously treated with cisplatin/gemcitabine.

Disclosures: Dr. Lamarca reported disclosures related to Eisai, Nutricia, Ipsen, Merck, Novartis, Pfizer, Abbott Nutrition, Advanced Accelerator Applications, Bayer, Celgene, Delcath Systems, Mylan, NanoString Technologies, and Sirtex Medical.

Citation:

Lamarca A et al. ASCO 2019, Abstract 4003.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,